End-of-day quote
Taipei Exchange
23:00:00 15/05/2024 BST
|
5-day change
|
1st Jan Change
|
183.5
TWD
|
0.00%
|
|
-2.65%
|
+168.67%
|
Fiscal Period: December |
2020
|
2021
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
5,194
|
6,117
|
11,268
|
30,273
|
-
|
Enterprise Value (EV)
1 |
5,194
|
6,117
|
11,268
|
30,014
|
29,319
|
P/E ratio
|
-
|
-
|
-46.5
x
|
-68.2
x
|
38.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
240
x
|
352
x
|
-
|
513
x
|
37.1
x
|
EV / Revenue
|
240
x
|
352
x
|
-
|
509
x
|
35.9
x
|
EV / EBITDA
|
-
|
-
|
-
|
-170
x
|
59.3
x
|
EV / FCF
|
-
|
-13.5
x
|
-
|
-63.7
x
|
61.3
x
|
FCF Yield
|
-
|
-7.4%
|
-
|
-1.57%
|
1.63%
|
Price to Book
|
-
|
3.1
x
|
-
|
22.9
x
|
17
x
|
Nbr of stocks (in thousands)
|
147,345
|
151,973
|
164,974
|
164,974
|
-
|
Reference price
2 |
35.25
|
40.25
|
68.30
|
183.5
|
183.5
|
Announcement Date
|
25/03/21
|
04/03/22
|
01/04/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
21.65
|
17.36
|
-
|
59
|
816
|
EBITDA
1 |
-
|
-
|
-
|
-177
|
494
|
EBIT
1 |
-
|
-430.3
|
-
|
-387.3
|
381.5
|
Operating Margin
|
-
|
-2,478.27%
|
-
|
-656.5%
|
46.75%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-444
|
1,035
|
Net income
1 |
-322.6
|
-
|
-238
|
-444
|
786
|
Net margin
|
-1,489.83%
|
-
|
-
|
-752.54%
|
96.32%
|
EPS
2 |
-
|
-
|
-1.470
|
-2.690
|
4.760
|
Free Cash Flow
1 |
-
|
-452.7
|
-
|
-471
|
478
|
FCF margin
|
-
|
-2,607.34%
|
-
|
-798.31%
|
58.58%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
96.76%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
60.81%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/03/21
|
04/03/22
|
01/04/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.634
|
10.06
|
4.463
|
15
|
18
|
20
|
6
|
EBITDA
1 |
-
|
-
|
-78.77
|
-92
|
-91
|
-90
|
-
|
EBIT
1 |
-103.2
|
-149.8
|
-80.87
|
-101
|
-99
|
-88
|
-85
|
Operating Margin
|
-16,279.02%
|
-1,488.23%
|
-1,812.03%
|
-673.33%
|
-550%
|
-440%
|
-1,416.67%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-117.6
|
-103
|
-110
|
-109
|
-
|
Net income
1 |
-
|
-
|
-115.6
|
-96
|
-103
|
-102
|
-
|
Net margin
|
-
|
-
|
-2,590.61%
|
-640%
|
-572.22%
|
-510%
|
-
|
EPS
2 |
-
|
-
|
-0.7100
|
-0.5800
|
-0.6200
|
-0.6200
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/11/21
|
04/03/22
|
14/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
259
|
954
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-453
|
-
|
-471
|
478
|
ROE (net income / shareholders' equity)
|
-
|
5.18%
|
-
|
-39.3%
|
6.9%
|
ROA (Net income/ Total Assets)
|
-
|
4.64%
|
-
|
-31.6%
|
9.19%
|
Assets
1 |
-
|
-
|
-
|
1,404
|
8,553
|
Book Value Per Share
2 |
-
|
13.00
|
-
|
8.000
|
10.80
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-2.220
|
2.990
|
Capex
1 |
-
|
0.09
|
-
|
12.5
|
11
|
Capex / Sales
|
-
|
0.5%
|
-
|
21.19%
|
1.35%
|
Announcement Date
|
25/03/21
|
04/03/22
|
01/04/24
|
-
|
-
|
Last Close Price
183.5
TWD Average target price
233.3
TWD Spread / Average Target +27.16% Consensus |
1st Jan change
|
Capi.
|
---|
| +168.67% | 942M | | +7.84% | 113B | | +10.37% | 106B | | +0.41% | 22.27B | | -12.02% | 22.22B | | -5.99% | 19.43B | | -37.36% | 17.87B | | -5.92% | 17.24B | | +7.12% | 14.29B | | +36.44% | 12.52B |
Bio Therapeutic Drugs
|